“Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)” and “Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES) trial” suggested a 15% reduction in the relative risk of the primary cardiovascular event composite endpoint with PCSK9 monotherapy compared with placebo (Sabatine et al., 2015; Schwartz et al., 2018). Here, PCSK9 is linked to acute coronary syndrome.